Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Effects of New Premium Must Be Verified: New Chuikyo Pricing Subcommittee Chairman
July 12, 2010
- JMHA to Survey Drugs Purchased by Its Member Hospitals Every Year
July 12, 2010
- JPMA Calls on Its Members Not to Refer to Premium When Negotiating Prices
July 12, 2010
- Eisai Licenses Lorcaserin from Arena in the US
July 12, 2010
- Acute-Stage Hospitals Concerned about Increases in Drug Purchase Costs
July 12, 2010
- Pfizer to Strengthen Drug Discovery Alliances in Japan
July 12, 2010
- Council Recommends Approval for 2 Advanced Therapies
July 12, 2010
- Council Holds Hearing on Immunization Programs
July 12, 2010
- Merck Serono Recommences PIII for Stimuvax in NSCLC
July 12, 2010
- Shionogi to Create Its Own Marketing Network in Asia
July 12, 2010
- Yakult Applies for XELOX Regimen for Colon Cancer
July 12, 2010
- Kissei's KUC-7483 Fails to Meet Efficacy Endpoint
July 12, 2010
- ASKA's Mid-Term Management Plan Calls For ¥48 Bil. Sales in FY2012
July 12, 2010
- Pariet Approved for Non-Erosive GERD in Japan: Eisai
July 12, 2010
- ASP1941 Fund to Reduce HbA1c in Japanese Patients in PII: Astellas
July 12, 2010
- Nippon Kayaku Aims at Doubling Pharma Sales to ¥100 Bil. in FY2015
July 12, 2010
- Janssen Applies for Golimumab for RA
July 12, 2010
- Omnaris HFA Meets Primary Endpoint for Efficacy in PIII: DSP
July 12, 2010
- AZ to Expand Production Capacity at Its Maibara Plant
July 12, 2010
- Banyu Applies for Vorinostat for CTCL in Japan
July 12, 2010
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…